CD3E and acute lymphoblastic leukemia: These increases in CD3ε expression in ETP-ALL cells may reflect enhanced differentiation and was only observed with SP2509 and not with GSK-LSD1i and was not modified in the presence of Ruxolitinib/JAKi within a 72-hour timeframe (Fig. 6D).